

Falk Symposium

179



Revisiting IBD Management: Dogmas to be Challenged

September 30 – October 1, 2011

Sheraton Brussels Hotel

Belgium



Preliminary Program

**Application for
CME credits
submitted**

▶	Preface	4
▶	Scientific Program	6
▶	Posters	11
▶	List of Speakers	12
▶	Information	17

CME credits for the Falk Symposium 179 have been applied for at the European Union of Medical Specialists (UEMS) – European Board of Gastroenterology (EBG). The number of credits awarded will be printed in the final program.

Preface

The field of inflammatory bowel disease is rapidly evolving. Our knowledge of genetic predisposition, immunological mechanisms and disease behaviour has never expanded as widely as in the last decade. Our tools to accurately visualize the extent and severity of inflammation and to detect dysplasia and cancer have become highly reliable. The list of novel small molecules and biologic agents targeting various mechanisms in the inflammatory cascade and in the vascular adhesion system is virtually endless.

Yet, many relevant questions remain unanswered when it comes to daily IBD management.

What is the optimal target for disease control? Why does IBD often 'escape' despite a time window of successful response to certain treatments? Why does the disease behaviour sometimes change drastically during the disease course? Why is postoperative recurrence of Crohn's disease virtually inevitable?

Although we have been convinced that we had found many answers to these questions, we need to realize that many such 'dogmas' need to be questioned and readdressed.

The 106th FALK symposium wishes to contribute to this critical attitude vis à vis 'ancient beliefs' in the field of IBD. The era of evidence based medicine forces us to critically review scientific data, to rephrase certain standards and, above all, to translate novel insights into the daily care for our patients.

As scientific organizers of this symposium, we hope that you will join us on this exciting scientific and clinical journey through the world of IBD. We hope to go home with a clearer view of the intriguing enigma that is IBD.

Geert D'Haens MD, PhD

Also on behalf of Severine Vermeire and Axel Dignass



Revisiting IBD Management: Dogmas to be Challenged

Sheraton Brussels Hotel
Belgium

Registration:

Thursday September 29, 2011
16.00 – 21.00 h
at the congress office

Information:

Prof. Dr. Geert D'Haens
Academic Medical Centre
Department of Gastroenterology
Meibergdreef 9
1105 AZ Amsterdam
The Netherlands
Telephone: +31(0)20/5 66 41 09
Telefax: +31(0)20/6 91 70 33
E-Mail: gdhaens@amc.uva.nl

Official Language:

English

Scientific Organization:

G. D'Haens, Amsterdam (The Netherlands)
A. Dignass, Frankfurt (Germany)
S. Vermeire, Leuven (Belgium)

Call for posters:

For details see page 11

Congress Venue:

Sheraton Brussels Hotel
Place Rogier 3
1210 Brussels
Belgium

Publication date of final program:

September 2011

The final program will be available on the homepage www.falkfoundation.org one week before.



Friday, September 30, 2011

9.00 Welcome

G. D'Haens,
Amsterdam

Dogma 1 – IBD is a disorder of defective autophagy and innate immunity

Chair: S. Danese, Rozzano; J. Satsangi, Edinburgh

9.05 Introduction

S. Danese,
Rozzano

9.10 Evidence from genetics for the role of autophagy and innate immunity in pathogenesis of IBD

M. Parkes,
Cambridge

9.40 Bacterial interactions with innate mucosal immunity

E. Cario,
Essen

10.05 Endoplasmatic reticulum stress and inflammation

A. Kaser,
Innsbruck

10.30 How can innate immunity be stimulated or “corrected”?

F. Pallone,
Rome

10.55 Wrap-up

J. Satsangi,
Edinburgh

11.00 Coffee break with poster session

Dogma 2 – No bacteria, no IBD

Chair: A. Darfeuille-Michaud, Clermont-Ferrand; W. M. de Vos, Wageningen

11.20 Introduction

A. Darfeuille-
Michaud,
Clermont-Ferrand

11.25 Lessons from diversion studies and antibacterial interventions

J. M. Rhodes,
Liverpool

11.45 Pouchitis and the role of bacteria in prevention and treatment of IBD

B. Shen,
Cleveland

12.05 The role of anti(myco)bacterial interventions in the current management of IBD: Is there evidence at all?

J.-F. Colombel,
Lille

12.30 The gut microbiome in health and IBD: Targets for the future?

J. Raes,
Brussels

12.55 Wrap-up

W. M. de Vos,
Wageningen

13.00 Lunch break with poster session



Friday, September 30, 2011

Dogma 3 – TNF plays a pivotal role in IBD

Chair: P. Rutgeerts, Leuven; H. Tilg, Innsbruck

- | | | |
|--------------|--|-----------------------------------|
| 14.00 | Introduction | P. Rutgeerts,
Leuven |
| 14.05 | Is efficacy of anti-TNF therapy really related to neutralisation of TNF and apoptosis? | G. R. van den Brink,
Amsterdam |
| 14.30 | Mechanisms of relapse and loss of response to anti-TNF treatment | M. Allez,
Paris |
| 14.55 | Anti-TNF therapy in CD and UC: Similar diseases, similar efficacy? | R. Panaccione,
Calgary |
| 15.15 | Therapeutic alternatives after failure of anti-TNF treatment for IBD | J. Satsangi,
Edinburgh |
| 15.35 | Wrap-up | H. Tilg,
Innsbruck |
| 15.40 | Coffee break with poster session | |

Dogma 4 – Steroids are useful for the management of IBD

Chair: G. D'Haens, Amsterdam; S. B. Hanauer, Chicago

- | | | |
|--------------|--|------------------------------|
| 16.00 | Introduction | S. B. Hanauer,
Chicago |
| 16.05 | Do steroids have an adverse effect on IBD outcome and healing? | G. van Assche,
Leuven |
| 16.25 | Pathophysiological changes during steroid treatment for IBD | Y. Chowers,
Tel Hashomer |
| 16.50 | Steroids with biologicals: Allies or enemies? | B. G. Feagan,
London (ON) |
| 17.15 | Novel steroid formulations: Higher efficacy, less toxicity? | S. Danese,
Rozzano |
| 17.40 | Wrap-up | G. D'Haens,
Amsterdam |
| 17.45 | End of afternoon session | |



Saturday, October 1, 2011

Dogma 5 – Early and late Crohn’s disease are distinct entities

Chair: G. Mantzaris, Athens; C. J. van der Woude, Rotterdam

- | | | |
|--------------|---|--------------------------------|
| 8.30 | Introduction | C. J. van der Woude, Rotterdam |
| 8.35 | Epidemiology of transition from early to late Crohn’s disease | E. Louis, Liège |
| 8.55 | Markers that differentiate early from late IBD | S. Kugathasan, Atlanta |
| 9.20 | Can fibrosis be prevented in Crohn’s disease? | M. Sans Cuffi, Barcelona |
| 9.45 | Can we slow down evolution from early to late CD? | S. Schreiber, Kiel |
| 10.10 | Wrap-up | G. Mantzaris, Athens |
| 10.15 | Coffee break with poster session | |

Dogma 6 – Innovative treatments will offer a better outcome for patients with IBD

Chair: S. Schreiber, Kiel; S. P. L. Travis, Oxford

- | | | |
|--------------|--|-------------------------|
| 10.45 | Introduction | S. P. L. Travis, Oxford |
| 10.50 | Biologic therapies: Lessons from MS | S. Ghosh, Calgary |
| 11.15 | Current status of mesenchymal stem cell and bone marrow transplantation in IBD | D. W. Hommes, Leiden |
| 11.35 | Resetting the mucosal immune system: Dream or reality? | T. T. MacDonald, London |
| 12.00 | Old wine in new bags: 5-ASA revisited? | A. Dignass, Frankfurt |
| 12.25 | Wrap-up | S. Schreiber, Kiel |
| 12.30 | Lunch break with poster session | |



Saturday, October 1, 2011

13.30 Presentation of Poster Prizes

Scientific
Committee

Dogma 7 – Patient tailored therapies are superior to algorithmic approaches in IBD

Chair: F. Baert, Roeselare; B. G. Feagan, London (ON)

13.40 Introduction

F. Baert,
Roeselare

13.45 Predicting the disease course from diagnosis

J. Panés,
Barcelona

14.10 How to guide therapeutic decisions in a patient-tailored approach?

P. Rutgeerts,
Leuven

14.35 Pharmacogenetics and prediction of therapy success

D. McGovern,
Los Angeles

15.00 Approach to IBD: Treating the disease or the patient? How I do it.

S. B. Hanauer,
Chicago

15.20 Wrap-up

B. G. Feagan,
London (ON)

15.25 Coffee break with poster session

Dogma 8 – Immunosuppression puts IBD patients at risk for severe complications

Chair: J.-F. Colombel, Lille; D. Franchimont, Brussels

15.55 Introduction

D. Franchimont,
Brussels

16.00 Combined immunosuppression is more dangerous than monotherapy: What is fact and what is rumor

J. Schölmerich,
Frankfurt

16.20 Prevention and management of infectious complications in IBD

J. F. Rahier,
Yvoir

16.40 Lymphoma and cancer in IBD: Can they be prevented?

L. Beaugerie,
Paris

17.00 How to manage IBD in patients with infections or malignancies?

A. Kohn,
Rome

17.20 Wrap-up

J.-F. Colombel,
Lille



Saturday, October 1, 2011

Wrap-up session

Leaving the dogmas behind and looking into the future

Chair: M. de Vos, Gent; R. Panaccione, Calgary

- | | | |
|--------------|--|--------------------------|
| 17.25 | Towards a novel molecular classification of IBD | S. Vermeire,
Leuven |
| 17.40 | Towards objective disease measurement | M. de Vos, Gent |
| 17.55 | Towards individualized therapeutic approaches in IBD | G. D'Haens,
Amsterdam |
| 18.10 | Toward a "cure" for IBD | C. Fiocchi,
Cleveland |
| 18.30 | Discussion | |
| 18.40 | End of meeting | |

Poster Session

Posters will be exhibited on September 30 and October 1, 2011, at the Sheraton Brussels Hotel. The authors will be in attendance during coffee and lunch breaks on both days.

Call for posters

Please submit your poster abstract before **May 15, 2011**. Only one-page abstracts not exceeding 250 words, written in English and saved in Microsoft Word format will be accepted.

Abstracts must be submitted via our Internet Abstract Submission System (<http://www.falkfoundation.com/poster>) where further information regarding the submission format and the submission process is available.

The abstracts will be selected by the scientific organizers, preference being given to those thematically related to one of the sessions of the program.

The accepted abstracts will be printed and distributed to the participants of the congress together with the documents of the meeting.

The authors will receive notification about acceptance and further instructions in **June 2011**.

Contact address for further information on the poster session:

Falk Foundation e.V.
P.O. Box 6529
79041 Freiburg/Germany
Telephone: +49 (0) 761 / 15 14 - 0
Telefax: +49 (0) 761 / 15 14 - 359
Web address for submitting poster abstracts:
<http://www.falkfoundation.com/poster>

For the **first author** of an accepted **poster**, expenses for accommodation (September 29 – October 2, 2011) and fees for the scientific program and evening activities will be covered during the Falk Symposium 179.

Travel expenses are not covered.

Poster prizes

Three prizes will be awarded for the best presentations.

Prize winners will be presented with a prize certificate and cheques for € 1.500,-, € 1.000,- and € 500,- respectively. Travel expenses will be covered additionally for the first author of prize winning posters.

List of Speakers, Moderators and Scientific Organizers

Dr. Matthieu Allez

Hôpital Saint-Louis
Service de Gastroentérologie
1 Ave. C. Vellefaux
75010 Paris
France
matthieu.allez@sls.aphp.fr

Dr. Filip Baert

Heilig Hart Ziekenhuis
Gastro-enterologie
Wilgenstraat 2
8800 Roeselare
Belgium
fbaert@hr.be

Dr. Laurent Beaugierie

Hôpital Saint Antoine
Department of Gastroenterology
184, Rue du Faubourg St.-Antoine
75571 Paris
France
laurent.beaugerie@sat.aphp.fr

Prof. Dr. Elke Cario

Gastroenterologie / Laboratorien
Universitätsklinikum Essen
Virchowstr. 179
45147 Essen
Germany
elke.cario@uni-due.de

Dr. Yehuda Chowers

Chaim Sheba Medical Center
Department of Gastroenterology
2 Sheba Road
52 621 Tel Hashomer
Israel
ychowers@post.tau.ac.il

Prof. Dr. Jean-Frederic Colombel

Hôpital Claude Huriez
CHRU Lille
Gastroenterology & Hepatology
1, Place de Verdun
59037 Lille
France
jfcolumbel@chru-lille.fr

Dr. Silvio Danese

Istituto Clinico Humanitas
IRCCS in Gastroenterology
Via Manzoni, 56
20089 Rozzano
Italy
sdanese@hotmail.com

Dr. Arlette Darfeuille-Michaud

Université d'Auvergne
CBRV
Laboratoire de Bactériologie
Pathogénie Bactérienne Intest.
26 Place H. Dunant
63000 Clermont-Ferrand
France
arlette.darfeuille-michaud@u.clermont1.fr

Prof. Dr. Martine de Vos

Rijksuniversiteit Gent
Universitair Ziekenhuis
Gastro-entérologie
De Pintelaan 185
9000 Gent
Belgium
martine.devos@rug.ac.be

Prof. Dr. Willem M. de Vos

Wageningen University
Laboratory of Microbiology
Dreijenplein 10
6703 HB Wageningen
Netherlands
willem.devos@wur.nl

Dr. Geert D'Haens

Academic Medical Center
Department of Gastroenterology
Meibergdreef 9
1105 AZ Amsterdam
Netherlands
gdhaens@amc.uva.nl

Prof. Dr. Axel Dignass

Innere Medizin I
Markus-Krankenhaus
Wilhelm-Epstein-Str. 4
60431 Frankfurt
Gemany
axel.dignass@fdk.info

Dr. Brian G. Feagan

University of Western Ontario
Robarts Research Institute
LCTRG
100 Perth Drive
London ON N6A 5K8
Canada
bfeagan@robarts.ca

Claudio Fiocchi, M.D.

Professor of Medicine
The Cleveland Clinic Foundation
Pathobiology / NC 20
9500 Euclid Avenue
Cleveland OH 44195
USA
fiocchc@ccf.org

Dr. Denis Franchimont

Université Libre de Bruxelles
Hôpital Erasme
Gastro-entérologie
Route de Lennik 808
1070 Bruxelles
Belgium
Denis.Franchimont@erasme.ulb.ac.be

Prof. Dr. Subrata Ghosh

University of Calgary
Health Sciences Centre
Department of Gastroenterology
3330 Hospital Drive N.W.
Calgary AB T2N 4N1
Canada
ghosh@ucalgary.ca

Stephen B. Hanauer, M.D.

Professor of Medicine
University of Chicago
Department of Medicine
Gastroenterology Section
5841 S. Maryland Ave.
Chicago IL 60637-1463
USA
shanaauer@medicine.bsd.uchicago.edu

Prof. Dr. Daan W. Hommes

Academisch Ziekenhuis Leiden
Afd. MDL C4 P
Albinusdreef 2
2333 ZA Leiden
Netherlands
d.w.hommes@lumc.nl

Dr. Arthur Kaser

Universitätsklinik Innsbruck
Klinische Abteilung für Gastro-
enterologie und Hepatologie
Anichstr. 35
6020 Innsbruck
Austria
arthur.kaser@i-med.ac.at

Dr. Anna Kohn

Azienda Ospedaliera
San Camillo-Forlanini
Divisione di Gastroenterologia
Dipartimento Scienze Mediche
Circonv. Gianicolense 100
00149 Rome
Italy
akohn@scamilloforlanini.rm.it

Subra Kugathasan, M.D.

Assoc. Professor of Pediatrics
Emory University
School of Medicine
Department of Pediatrics
201 Dowman Drive
Atlanta GA 30322
USA
skugath@emory.edu

Dr. Edouard Louis

C.H.U. Sart Tilman
Gastro-entérologie
Domain du Sart Tilman
4000 Liège
Belgium
edouard.louis@ulg.ac.be

Prof. Dr. Thomas T. MacDonald

Barts & The London/Queen Mary's
School of Medicine & Dentistry
Centre for Infectious Disease
Inst. of Cell & Molecular Sc.
4 Newark Street, Whitechapel
London E1 2AT
Great Britain
t.t.macdonald@qmul.ac.uk

Dr. Gerassimos Mantzaris

Evangelismos Hospital
Dept. of Gastroenterology
45-47, Ipsilantou str.
106 75 Athens
Greece
gman195@yahoo.gr

Dermot McGovern, M.D.

Associate Professor of Medicine
Cedars-Cinai Medical Center
Inflammatory Bowel Disease Ctr.
& Immunology Inst., Suite 2E
8730 Alden Drive
Los Angeles CA 90048
USA
dermot.mcgovern@cshs.org

Prof. Dr. Francesco Pallone

Università di Roma
Cattedra di Gastroenterologia
Dipartimento di Medicina Interna
Viale Montpellier, 1
00133 Rome
Italy
pallone@med.uniroma2.it

Prof. Dr. Remo Panaccione

University of Calgary
Inflammatory Bowel Disease
Clinic, Room 6D30, TRW Building
3280 Hospital Drive N.W.
Calgary AB T2N 2T9
Canada
rpanacci@ucalgary.ca

Dr. Julián Panés

Hospital Clinico y Provincial
Universidad de Barcelona
Inflammatory Bowel Disease Unit
c/ Villarroel no. 170
08036 Barcelona
Spain
jpanes@clinic.ub.es

Dr. Miles Parkes

University of Cambridge
Addenbrookes Hospital
Gastroenterology Unit
Hills Road
Cambridge CB2 0QQ
Great Britain
miles.parks@addenbrookes.nhs.uk

Dr. Jeroen Raes

VIB
Department of Molecular
& Cellular Interactions
Pleinlaan 2
1050 Bruxelles
Belgium
jeroen.raes@vib-vub.be

Dr. J. F. Rahier

U.C.L. Mont Godinne
Av. Dr. Therasse 1
5530 Yvoir
Belgium
jfracier@gmail.com

Prof. Dr. Jonathan M. Rhodes

University of Liverpool
Gastroenterology Research Group
Duncan Building
P.O. Box 147
Liverpool L69 3BX
Great Britain
rhodesjm@liverpool.ac.uk

Prof. Dr. Paul Rutgeerts

University Ziekenhuis
Gasthuisberg
Gastro-entérologie
Herestraat 49
3000 Leuven
Belgium
paul.rutgeerts@uz.kuleuven.ac.be

Dr. Miquel Sans Cuffi

Hospital Clinico y Provincial
Universidad de Barcelona
Inflammatory Bowel Disease Unit
c/ Villarroel no. 170
08036 Barcelona
Spain
msans@clinic.ub.es

Prof. Dr. Jack Satsangi

University of Edinburgh
Western General Hospital
Gastrointestinal Unit
Crewe Road
Edinburgh EH4 2XU
Great Britain
j.satsangi@ed.ac.uk

Prof. Dr. Jürgen Schölmerich

Klinikum der Johann Wolfgang
Goethe-Universität Frankfurt
Theodor-Stern-Kai 7
60596 Frankfurt
Germany
jurgens.schoelmerich@kgu.de

Prof. Dr. Stefan Schreiber

Innere Medizin I
Universitätsklinikum
Schleswig-Holstein, Campus Kiel
Schittenhelmstr. 12
24105 Kiel
Germany
s.schreiber@1med.uni-kiel.de

Bo Shen, M.D.

The Cleveland Clinic Foundation
Gastroenterology & Hepatology
Mail Code A30
9500 Euclid Avenue
Cleveland OH 44195
USA
shenb@ccf.org

Prof. Dr. Herbert Tilg

Bezirkskrankenhaus
Hall i.T.
Interne Abt.
Milsrerstr. 10
6060 Hall / Tirol
Austria
herbert.tilg@i-med.ac.at

Dr. Simon P.L. Travis

John Radcliffe Hospital
NHS Trust
Department of Gastroenterology
Headley Way Headington
Oxford OX3 9DU
Great Britain
simon.travis@ndm.ox.ac.uk

Prof. Dr. Gert van Assche

University Ziekenhuis
Gasthuisberg
Gastro-entérologie
Herestraat 49
3000 Leuven
Belgium
gert.vanassche@uz.kuleuven.ac.be

Dr. G. R. van den Brink

Univ. van Amsterdam, Tytgat Inst
for Liver & Intestinal Research
Laboratory of Experimental
Medicine, Room G2-130
Meibergdreef 9
1105 AZ Amsterdam
Netherlands
g.r.vandenbrink@amc.uva.nl

Dr. C. Janneke van der Woude

Erasmus Medical Center
Afd. Gastroenterologie
,s-Gravendijkwal 230
3015 CE Rotterdam
Netherlands
c.vanderwoude@erasmus.nl

Prof. Dr. Severine Vermeire

University Ziekenhuis
Gasthuisberg
Gastro-entérologie
Herestraat 49
3000 Leuven
Belgium
severine.vermeire@uz.kuleuven.ac.be

General Information

Prior to the opening of the congress in Brussels

Falk Foundation e. V.	Telephone: +49 (0) 761 / 15 14 - 0
Congress Division	Telefax: +49 (0) 761 / 15 14 - 359
Leinenweberstr. 5	E-mail: symposia@falkfoundation.de
P.O. Box 6529	
79041 Freiburg/Br. (Germany)	

Congress Office

During the Falk Symposium 179

Sheraton Brussels Hotel	Telephone: +32 (0) 2 / 224 38 01
Place Rogier 3	Telefax: +32 (0) 2 / 224 30 01
1210 Brussels	
Belgium	

Opening Hours:

Thursday, September 29, 2011	16.00 – 21.00 h
Friday, September 30, 2011	8.00 – 18.00 h
Saturday, October 1, 2011	8.00 – 18.40 h

Congress Fees

Scientific program of the Falk Symposium 179	€ 200,-
Students and residents	€ 100,-

*** * * OR * * ***

Day ticket	€ 120,-
Students and residents	€ 60,-

The congress fees include:

- Welcome Evening on September 29, 2011
- Refreshments during coffee breaks
- Lunch on September 30 and October 1, 2011
- A copy of the abstract volume

Registration

Congress registrations must reach the Falk Foundation e.V. by **July 31, 2011 at the latest**. Congress fees may be paid by cheque payable to the Falk Foundation e.V. or by bank transfer to Volksbank Freiburg e.G., Germany, Bank No. 68090000, Account No. 1452010, IBAN DE33 6809 0000 0001 4520 10, BIC Genode 61 FR1. Please mark bank transfers with „Falk Symposium 179“.

To ensure correct registration, participants are asked to send in their registration and the fee remittance together.

After receipt of registration form, each participant will be provided with confirmation of his registration. On presentation of this confirmation at the Congress Office in Brussels participants will receive the congress folder containing name badges, admission tickets and the abstract volume.

In the event of registration cancellations, a handling fee of EUR 20,- will be deducted from the refund. All participants will receive a written confirmation of attendance at the end of the meeting.

Admission to Scientific Events

For admission to scientific events your name badge should be clearly visible.

Hotel Accommodation

Hotel reservations can be made online:
www.booking.com/hotels

Congress Report

The official congress report of the Falk Symposium 179 “Revisiting IBD Management: Dogmas to be Challenged” will be published in English in the first half of 2012 by Karger Publishers, Basel, Switzerland. Orders for this book at a reduced subscription price of € 35.- can be placed at the Congress Office during the congress in Brussels.

Congress Short Report

The congress short report of the Falk Symposium 179 will be published by the Falk Foundation e.V. with number FSK 179 in the first half on 2012.

Orders for this short report, free of charge, can be placed with the Falk Foundation e.V.

Airport

International Airport Brussels



Falk Foundation
Dr. Falk Pharma



*Where medicine
and pharmaceuticals meet –
a tried and trusted link*

Innovative Drugs

for bowel and liver diseases

Modern formulations and specially designed delivery systems ensure targeted release of the active drug

Scientific Dialogue

in the interest of therapeutic progress

Falk Symposia and Workshops

nearly 250, attended by more than 100,000 participants from over 100 countries since 1967

Continuing medical education seminars

over 14,000, attended by more than one million physicians and patients in Germany alone

Comprehensive literature service for healthcare professionals and patients

with more than 200 publications

www.falkfoundation.org

www.drFalkpharma.com

Leinenweberstr. 5 79108 Freiburg Germany Tel +49 (0)761/1514-0 Fax +49 (0)761/1514-321 Mail zentrale@drfalkpharma.de



General Information:

FALK FOUNDATION e.V.



Leinenweberstr. 5
79108 Freiburg
Germany

Congress Division

Telephone: +49(0)761/1514-0

Telefax: +49(0)761/1514-359

E-mail: symposia@falkfoundation.de

www.falkfoundation.org